Table 3.

ANCOVA results comparing baseline and 3-month follow-up scores for QoL measures

	All patients (n=518)	Recurrent AT/AF (n=154)	No recurrent AT/AF (n=364)	P value
EQ-5D total
Baseline	0.79 (0.22)	0.78 (0.21)	0.79 (0.22)
End of study	0.83 (0.20)	0.78 (0.21)	0.84 (0.20)
Change	0.04 (0.21)	0.00 (0.21)	0.05 (0.21)	0.131
SF-12 mental component
Baseline	49.78 (9.61)	50.07 (9.22)	49.67 (9.78)
End of study	51.79 (9.24)	49.94 (9.72)	52.58 (8.93)
Change	2.01 (9.26)	−0.12 (9.09)	2.91 (9.19)	0.065
SF-12 physical component
Baseline	44.31 (9.07)	42.57 (9.07)	45.04 (8.98)
End of study	47.40 (8.69)	44.43 (9.33)	48.66 (8.09)
Change	3.10 (8.24)	1.86 (8.93)	3.62 (7.88)	0.238
Karnofsky
Baseline	86.3 (10.2)	85.8 (11.2)	86.5 (9.8)
End of study	93.2 (9.7)	90.6 (11.4)	94.3 (8.6)
Change	7.0 (9.7)	4.9 (9.6)	7.9 (9.6)	<0.001
MoCA
Baseline	26.6 (2.8)	27.1 (2.5)	26.3 (2.9)
End of study	27.2 (2.8)	27.7 (2.6)	27.0 (2.9)
Change	0.6 (2.5)	0.6 (2.3)	0.7 (2.6)	0.924

The p value in this table corresponds to the effect of recurrent AT/AF group in an ANCOVA model with change from baseline as the dependent variable, and baseline values and recurrent AT/AF group as covariates.

AF, atrial fibrillation; ANCOVA, analysis of covariance; AT, atrial tachycardia; MoCA, Montreal Cognitive Assessment; QoL, quality of life.